Groundbreaking discoveries using MRI technology to help elevate population health outcomes
At a glance
Empowering providers to discover how to fight the most debilitating illnesses with the latest MRI technology
We are helping enable groundbreaking discoveries with a wide array of research-focused MRI technology. This technology is enabling deeper exploration of care pathways to better understand the world’s most debilitating diseases like cancer, neurodegenerative, cardiovascular and psychological disorders.
Our vision is to empower you with technology rooted in research collaborations along with continued innovation in AI and advanced imaging applications. Our ultimate goal is to help you discover new biomarkers that could lead to significant breakthroughs in your understanding of disease, accelerate the translation of research to clinical practice, and provide new hope for all patients.
$25.2T
$612B+
500
34M+
Providing hope for all patients through innovations in MRI technology
From care to cure pathways
Enabling personalized oncology treatment with MRI
Explore neurology in a new way
Dedicated to exploring our most complex organ
A deeper understanding with AI
Intelligent AI innovation for insightful imaging
Enabling collaborations
Accelerating cutting-edge care through collaborations
References
2. Álvaro Nuno Perez, Jose Suarez, Michel Le Barsh, "Sizing the brain. Segmentation and growth factors of the global neuroscience market". Last modified: February, 14,2023. Https://www2.deloitte.com/us/en/insights/industry/health-care/global-neuroscience-market-investment-report.html
3. Per CTMS data as of 10/1/2024.
4. Calculated from installed base data as of September 2024 with estimation of 20 scans per day, 5.5 working days a week and fully utilizing AIR™ Recon DL 4 weeks after delivery.
5. SIGNA™ PET/MR AIR™ is a premium configuration of SIGNA™ PET/MR. Not available for sale in all regions.
6. It is the responsibility of the user to verify the contours and user-defined labels for each organ at risk and correct the contours/labels as needed.
7. SIGNA™ 7T is a configuration of SIGNA™ 7.0T. SIGNA™ 7.0T is 510(k) cleared. Not yet CE Marked. Not available for sales in all regions.
*SIGNA™ MAGNUS and ODEN are 510(k) cleared with the FDA. Not yet CE Marked. Not available for sale in all regions.
**MR Contour DL is 510(k) pending with the U.S. FDA. Not CE Marked in Europe. Not available for sales in all regions.